The bill amends the Public Health Code by adding Section 17757c, which establishes regulations for manufacturers, wholesalers, and wholesale distributor-brokers regarding the acquisition and delivery of 340B drugs. Specifically, it prohibits these entities from denying, restricting, or discriminating against 340B entities or authorized pharmacies in their acquisition of 340B drugs. However, exceptions are made if such actions are authorized by state or federal law. Additionally, starting July 1, 2026, 340B entities will be required to submit annual reports detailing their 340B program, including compliance with federal regulations and the impact of the program on the community.

Furthermore, the bill mandates that manufacturers report on prescription drugs that exceed $40.00 for a course of treatment and have seen a price increase of more than 15% in the past year. These reports must include comprehensive information about the drug, such as its cost history, production costs, and various forms of dispensation. The Department of Health will be responsible for posting these reports on its public website, ensuring transparency in the pricing and distribution of prescription drugs and 340B programs.

Statutes affected:
Senate Introduced Bill: 333.1101, 333.25211
As Passed by the Senate: 333.1101, 333.25211